Plazomicin Sulfate Patent Expiration
Plazomicin Sulfate is Used for treating bacterial infections. It was first introduced by Cipla Usa Inc
Plazomicin Sulfate Patents
Given below is the list of patents protecting Plazomicin Sulfate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zemdri | US8383596 | Antibacterial aminoglycoside analogs | Jun 02, 2031 | Cipla Usa |
| Zemdri | US8822424 | Antibacterial aminoglycoside analogs | Nov 21, 2028 | Cipla Usa |
| Zemdri | US9266919 | Antibacterial aminoglycoside analogs | Nov 21, 2028 | Cipla Usa |
| Zemdri | US9688711 | Antibacterial aminoglycoside analogs | Nov 21, 2028 | Cipla Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Plazomicin Sulfate's patents.
Latest Legal Activities on Plazomicin Sulfate's Patents
Given below is the list recent legal activities going on the following patents of Plazomicin Sulfate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| FDA Final Eligibility Letter Critical | 30 Jan, 2024 | US8383596 |
| FDA Final Eligibility Letter Critical | 30 Jan, 2024 | US8822424 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 23 Aug, 2023 | US9266919 |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2023 | US8383596 |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2023 | US8822424 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US8383596 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US8822424 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Mar, 2022 | US8822424 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Dec, 2020 | US9688711 |
| Second letter to regulating agency to determine regulatory review period | 24 Sep, 2020 | US8383596 |
Plazomicin Sulfate's Family Patents
